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Abstract
Objective: To explore asthma pathogenesis using data from upper and lower
airways.
Data Source: English-language papers on human asthma and nasal polyp subjects
from 1990 onwards.
Study Selection: High-quality studies in established journals.
Results: The recognition of its inﬂammatory nature led to a quantum leap in the
understanding and treatment of asthma, with lives saved by inhaled corticoste-
roids. Further work at genetic, molecular, histological and clinical levels has
shown that asthma is polymorphic and rarely involves isolated Th2 bronchial
inﬂammation.
Viral infections may act as an initiating event in children and adults, showing
synergy with atopy. Chronic staphylococcal colonization of the mucosa may act as
a promoter, as in atopic dermatitis. These two observations may be linked, with
viruses providing an entry for bacteria into the mucosal epithelium.
Conclusions: Most asthma begins in the nose and involves allergy and infection:
both viral and bacterial. The combination of atopy and infection suggests new
possibilities for therapy.
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The relationship between allergy and asthma has long
been the subject of debate. It is obvious that allergen
exposure in Immunoglobulin E (IgE)-sensitized asth-
matic subjects can provoke wheezing, shortness of
breath and falls in forced expiratory volume in 1
second (1). However, allergen avoidance and allergen-
speciﬁc immunotherapy have not proven consistently
effective in asthma (2, 3), which involves mechanisms
other than Th2 inﬂammation, such as Th1 inﬂam-
mation and remodeling (4, 5). Anti-IgE therapy has
reopened the issue: it is undoubtedly effective in
severe asthma (6), but it appears that eosinophils,
rather than IgE, may be a better biomarker for those
likely to beneﬁt, since non-atopic severe asthmatics
also respond (7), as do nasal polyps (8). Local IgE
formation, without evidence of sensitization at sys-
temic level, i.e. negative skin prick and blood IgE
tests, may provide an answer (9–12), since the im-
munopathology of allergic and intrinsic asthma is
similar (13).
An interaction between infection and allergy has
been noted: children with allergic rhinitis suffer more
and for longer with viral colds (14). Most acute
asthma exacerbations start in the nose with a viral
cold (15, 16). In allergic asthmatic children who are
exposed to the relevant allergen and who then catch a
cold, the odds ratio for hospital admission for asthma
is 19 (17).
In fact, asthma itself usually begins with nasal
disease.The European Community Respiratory Health
Survey data show that both allergic and non-allergic
rhinitis are risk factors for subsequent asthma devel-
opment (18).The combination of recurrent viral colds
and allergic rhinitis in children carries a high odds
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demonstrated between nose and chest by Braunstahl
et al. – showing that nasal allergen challenge provokes
inﬂammation in both the upper airway and the
bronchi,and vice versa – provides one possible mecha-
nism for the spread of inﬂammation from nose to
bronchi (20).
The pathogenesis of one asthma phenotype – non-
atopic (intrinsic) asthma associated with aspirin
sensitivity and nasal polyposis, known as aspirin exac-
erbated respiratory disease (AERD) – is becoming
unraveled.TheEuropeanNetworkonAspirin-Induced
Asthma provided information from over 500 sufferers
that the problem starts at age 29 ± 12 years with per-
sistent rhinitis, and with subsequent development of
nasal polyps, asthma and aspirin intolerance, in vari-
able order.The disease tends to occur earlier in females
and atopics (21).
The late Andrew Szczeklik suggested an initiating
viral upper respiratory tract infection, based on the
history given by many sufferers of being well until the
sudden onset of a severe cold, which never went away,
and upon the demonstration of virus-like particles
in the bronchial mucosa (22). Interferon gamma
hyperproduction, which differentiates AERD from
other forms of eosinophilic asthma (23), is in accord
with a chronic viral presence. Microorganisms other
than viruses may also be involved: Bachert and his
group have noted that nasal colonization with Staphy-
lococcus aureus is particularly high inAERD patients at
88%, compared with around 30% in control subjects,
and that most have formed IgE to staphylococcal
enterotoxins (24). These appear to be disease drivers
since they act as superantigens: activating over 20% of
T lymphocytes to elaborate cytokines such as IL5 and
IL4, which cause local polyclonal IgE production and
predominantly eosinophilic inﬂammation (12). The
systemic link is again apparent with elevated blood
eosinophilswhichmigrateoutof thebonemarrowand
localize in both the upper and lower airways (25).
Staphylococci are located within the mucosa and even
within cells in biopsy studies (26).
The presence of IgE to staphylococcal enterotoxins
in blood confers a risk factor of 7.25 (2.7–19.1) for
asthma and 11.09 (4.1–29.6) for severe asthma, where
59.6%of suffererswerepositivecomparedwith13%of
controls (27).
These observations:– origin in the nose with atopy,
systemicorlocal,asafactor;possibleviralco-initiation
and staphylococcal promotion – have been linked by
recent observations that herpes simplex virus can
penetratethenasalepitheliumandallowStaphylococci
to enter the mucosa (28, 29). Rhinoviruses, the most
frequent cause of the common cold, probably
behave similarly.There is,thus,a multi-hit initiation of
disease(Fig. 1),withepithelialgenesandthoseforbac-
terial and viral resistance probably relevant, as well as
those involved in atopy and remodeling (30, 31).
Repeated observations of sphingolipid abnormalities
in asthma may be relevant: sphingolipids are thought
to protect the cell surface against harmful environ-
mental factors by forming a mechanically stable and
chemically resistant outer leaﬂet of the plasma
membrane lipid bilayer. Polymorphisms controlling
orosomucoid-like 3 (ORMDL3) expression in the
asthma susceptibility locus 17q21 are associated with
childhood asthma, but not with atopy (32, 33), sug-
gesting that ORMDL3 affects asthma susceptibility
independentof atopicorimmunoglobulinE-mediated
pathways (33).
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Figure 1. Allergic-type asthma could result from a multi-hit
phenomenon: the primary event in the allergic airway is Th2
inﬂammation, usually arising in the upper airway (as rhinitis)
before progressing to the lower, where it is initially intermittent.
At this stage, the disease is amenable to treatments such as
allergen avoidance and immunotherapy. However, infections
such as rhinoviruses are handled less effectively by the inﬂamed
mucosa, possibly because of defects in interferons and/or
sphingolipids. Epithelial permeability is compromised, and per-
sistence of microorganisms such as Staphylococci is permitted.
This further perturbs local immunity with nonspeciﬁc activation
of T lymphocytes via V beta receptors and chronic local Th1,
Th17 and Th2 inﬂammation which is no longer as responsive to
anti-allergic treatment. Since the bacteria are intra-epithelial,
antibiotics cannot eliminate them. Topical corticosteroids are
useful as anti-inﬂammatories at all stages, but doses needed
rise as inﬂammation becomes more complex and persistent.
There is a continued attempt at tissue repair, evident as airways
remodeling. Non-allergic asthma could begin at stage 2.
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other bacteria,mycoplasma and fungi,that can initiate
or maintain asthma in a similar fashion in other phe-
notypes: allergic bronchopulmonary aspergillosis is
one example. The microbiome of induced sputum is
different in asthma compared with controls: patients
with mild asthma have an altered microbial composi-
tion in the respiratory tract that is similar to that
observed in patients with more severe asthma (34).An
IgE response to staphylococcal enterotoxins has also
beendemonstratedinadenoidtissuesfromatopicchil-
dren (35). Interestingly in teenagers, although Staphy-
lococci are implicated, some other microorganisms
appear protective (36).
This has important implications. The ﬁrst is that
there is possibly a window of opportunity for preven-
tion of asthma in allergic rhinitis.Grass pollen-speciﬁc
immunotherapy by the subcutaneous route probably
reduces asthma development (37); the sublingual
route is under investigation (38). If proven effective,
the threshold for its use should be reconsidered and
the preventative effects of immunotherapy for other
allergens, such as house dust mite, evaluated. Further-
more, pharmacotherapy for rhinitis used regularly
with good control of minimal persistent upper res-
piratory tract inﬂammation (39) might also reduce
progression to asthma, or reduce exacerbations in
those already suffering from associated asthma. This
needs exploration.
The second is that prevention of colds is vitally
important and the search for a cure needs to continue.
Whether amelioration of symptoms and inﬂammation
during a viral upper respiratory tract infection (URTI)
ishelpfulisunknown.Meanwhile,simplepublichealth
measures, such as hand washing, use of disposable
tissues, etc., should be taught. Vitamin D may be rel-
evant in protection against URTI, with low levels pre-
disposing to infection frequency and/or severity (40).
Finally, if the pro-inﬂammatory stimulus is infective
but intra-mucosal,then perhaps asthma therapy might
beneﬁt from a rethink. Inhaled corticosteroids are
obviously needed, but instead of additional chronic
anti-inﬂammatorytherapywithincreasinglyexpensive
or toxic molecules the idea of stimulus removal could
be mooted. Systemic antibiotics have shown some
effectiveness in asthma and in nasal polyposis associ-
atedwithasthma(41,42),butintra-mucosalorsurface
bioﬁlms are resistant to them and planktonic form
reemerge once the course is completed. Local use of
anti-microbials needs exploration. Bronchial thermo-
plasty, which destroys the respiratory epithelium,
mightactviabacterialkilling,inafashionanalogousto
the treatment of syphilis by heat (43).
The pathogenesis of asthma is unraveling further
and provides us with an opportunity by careful
research not only to improve the way in which patients
are treated, but possibly also to prevent some of them
from developing this lifelong, troubling and expensive
disease in the ﬁrst place.
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